Bruno BRUNO de Mattos Lombardi Badia

Mr. Bruno BRUNO de Mattos Lombardi Badia

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
ASAndré M. S. Silva
André M. S. Silva
ACAntônio R. Coimbra-Neto
Antônio R. Coimbra-Neto
PSPaulo Victor S. Souza
Paulo Victor S. Souza
PWPablo B. Winckler
Pablo B. Winckler
MGMarcus V. M. Gonçalves
Marcus V. M. Gonçalves
EZEdmar Zanoteli
Edmar Zanoteli
Objective: ANO5‐related myopathy is an important cause of limb‐girdle muscular dystrophy (LGMD) and hyperCKemia. The main descriptions have emerged from European cohorts, and the burden of the disease worldwide is unclear. We provide a detailed characterization of a large Brazilian cohort of ANO5 patients.Methods: A national cross‐sectional study was conducted to describe clinical, histopathological, radiological, and molecular features of patients carrying recessive variants in ANO5. Correlation of clinical and genetic characteristics with different phenotypes was studied.Results: Thirty‐seven patients from 34 nonrelated families with recessive mutations of ANO5 were identified. The most common phenotype was LGMD, observed in 25 (67.5%) patients, followed by pseudometabolic presentation in 7 (18.9%) patients, isolated asymptomatic hyperCKemia in 4 (10.8%) patients, and distal myopathy in a single patient. Nine patients presented axial involvement, including one patient with isolated axial weakness. The most affected muscles according to MRI were the semimembranosus and gastrocnemius, but paraspinal and abdominal muscles, when studied, were involved in most patients. Fourteen variants in ANO5 were identified, and the c.191dupA was present in 19 (56%) families. Sex, years of disease, and the presence of loss‐of‐function variants were not associated with specific phenotypes.Interpretation: We present the largest series of anoctaminopathy outside Europe. The most common European founder mutation c.191dupA was very frequent in our population. Gender, disease duration, and genotype did not determine the phenotype.

1 January 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
IFIgor Braga Farias
Igor Braga Farias
EGEduardo Augusto Gonçalves
Eduardo Augusto Gonçalves
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Background: Acute hepatic porphyrias represent an expanding group of complex inherited metabolic disorders due to inborn errors of metabolism involving heme biosynthesis. Objective: We aimed to review the main clinical and therapeutic aspects associated with acute hepatic porphyrias. Methods: The authors provided a wide non-systematic review of current concepts and recently acquired knowledge about acute hepatic porphyrias. Results: Acute neurovisceral attacks are the most common and life-threatening presentation of this group and are often considered the main clinical manifestation by clinicians during differential diagnosis and the start of proper diagnostic work-up for acute porphyrias. However, atypical presentations with central nervous system involvement, neuropsychiatric disturbances, and some subtypes with photosensitivity usually make the definite diagnosis difficult and late. Early therapeutic interventions are essential during emergency treatment and intercritical periods to avoid recurrent severe presentations. The availability of new disease-modifying therapeutic proposals based on small interfering RNA (siRNA)-based therapies, complementary to the classic intravenous glucose infusion and hemin-based treatments, emphasizes the importance of early diagnosis and genetic counseling of patients. Conclusions: This review article highlights the main biochemical, pathophysiological, clinical, and therapeutic aspects of acute hepatic porphyrias in clinical practice.

28 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
PSPaulo de Lima Serrano
Paulo de Lima Serrano
Igor Braga FariasIgor Braga Farias
Igor Braga Farias
Roberta Ismael Lacerda MachadoRoberta Ismael Lacerda Machado
Roberta Ismael Lacerda Machado
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Juvenile Amyotrophic Lateral Sclerosis is a genetically heterogeneous neurodegenerative disorder, which is frequently misdiagnosed due to low clinical suspicion and little knowledge about disease characteristics. More than 20 different genetic loci have been associated with both sporadic and familial juvenile Amyotrophic Lateral Sclerosis. Currently, almost 40% of cases have an identifiable monogenic basis; type 6, associated with FUS gene variants, is the most prevalent globally. Despite several upper motor neuron-dominant forms being generally associated with long-standing motor symptoms and slowly progressive course, certain subtypes with lower motor neuron-dominant features and early bulbar compromise lead to rapidly progressive motor handicap. For some monogenic forms, there is a well-established genotypic-phenotypic correlation. There are no specific biochemical and neuroimaging biomarkers for the diagnosis of juvenile Amyotrophic Lateral Sclerosis. There are several inherited neurodegenerative and neurometabolic disorders which can lead to the signs of motor neuron impairment. This review emphasizes the importance of high clinical suspicion, assessment, and proper diagnostic work-up for juvenile Amyotrophic Lateral Sclerosis.

1 October 2021 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
Wladimir Bocca Vieira de Rezende PintoWladimir Bocca Vieira de Rezende Pinto
Wladimir Bocca Vieira de Rezende Pinto
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
IFIgor Braga Farias
Igor Braga Farias
JFJosé Marcos Vieira de Albuquerque Filho
José Marcos Vieira de Albuquerque Filho
Acary Souza Bulle OliveiraAcary Souza Bulle Oliveira
Acary Souza Bulle Oliveira
Background: Adult-onset spinal muscular atrophy (SMA) represents an expanding group of inherited neurodegenerative disorders in clinical practice. Objective: This review aims to synthesize the main clinical, genetic, radiological, biochemical, and neurophysiological aspects related to the classical and recently described forms of proximal SMA. Methods: The authors performed a non-systematic critical review summarizing adult-onset proximal SMA presentations. Results: Previously limited to cases of SMN1-related SMA type 4 (adult form), this group has now more than 15 different clinical conditions that have in common the symmetrical and progressive compromise of lower motor neurons starting in adulthood or elderly stage. New clinical and genetic subtypes of adult-onset proximal SMA have been recognized and are currently target of wide neuroradiological, pathological, and genetic studies. Conclusions: This new complex group of rare disorders typically present with lower motor neuron disease in association with other neurological or systemic signs of impairment, which are relatively specific and typical for each genetic subtype.

1 November 2019 in Mitochondrion
Verified
Journal Article
Closed access
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
TBThiago Bortholin
Thiago Bortholin
CTCarlos Alberto Castro Teixeira
Carlos Alberto Castro Teixeira
DSDaniel Delgado Seneor
Daniel Delgado Seneor
VMVitor Dias Gomes Barrios Marin
Vitor Dias Gomes Barrios Marin
SDSalvatore DiMauro
Salvatore DiMauro

5 February 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
BBBruno BRUNO de Mattos Lombardi Badia
Bruno BRUNO de Mattos Lombardi Badia
PSPaulo de Lima Serrano
Paulo de Lima Serrano
JBJoão Paulo Barile
João Paulo Barile
DSDaniel Seneor
Daniel Seneor
PMPatrícia Marques Mendes
Patrícia Marques Mendes
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Background: Acute hepatic porphyrias (AHPs) represent inherited metabolic disorders of the heme biosynthesis pathway, leading to neurological and systemic impairment. Despite the presence of well-recognized chronic symptoms and signs, acute neurological, both neuromuscular and central neurological complications pose a significant challenge in clinical practice, with a potential risk of greater severity and mortality during acute decompensation episodes of AHPs. Care related to the prescription of medications, considering the risk of porphyrinogenicity, is a major and recurring concern in the acute and chronic management of AHP patients. Infectious clinical complications are significant issues in both outpatient and hospital settings for patients with AHPs. It is crucial to identify therapeutic regimens with the best safety and efficacy profiles for treating such infectious complications in AHP patients. The scarcity of structured knowledge available in guidelines and recommendations often leads to the use of therapeutic options with higher potential risks in treating patients with AHPs. Objectives: This review article aims to provide practical recommendations for managing the most significant infectious complications in clinical practice, with a focus on their impact on the clinical care of patients with AHPs.